217 related articles for article (PubMed ID: 37659730)
1. Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse.
Li Z; Shen L; Ma A; Talkington A; Li Z; Nyborg AC; Bowers MS; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
Acta Biomater; 2023 Oct; 170():250-259. PubMed ID: 37659730
[TBL] [Abstract][Full Text] [Related]
2. High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.
Talkington AM; McSweeney MD; Zhang T; Li Z; Nyborg AC; LaMoreaux B; Livingston EW; Frank JE; Yuan H; Lai SK
J Control Release; 2021 Oct; 338():804-812. PubMed ID: 34481925
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
[TBL] [Abstract][Full Text] [Related]
4. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
[TBL] [Abstract][Full Text] [Related]
5. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
[TBL] [Abstract][Full Text] [Related]
6. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA
Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice.
McSweeney MD; Shen L; DeWalle AC; Joiner JB; Ciociola EC; Raghuwanshi D; Macauley MS; Lai SK
J Control Release; 2021 Jan; 329():774-781. PubMed ID: 33038448
[TBL] [Abstract][Full Text] [Related]
8. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety.
Schlesinger N; Lipsky PE
Semin Arthritis Rheum; 2020 Jun; 50(3S):S31-S38. PubMed ID: 32620200
[TBL] [Abstract][Full Text] [Related]
9. Free PEG Suppresses Anaphylaxis to PEGylated Nanomedicine in Swine.
Shen L; Li Z; Ma A; Cruz-Teran C; Talkington A; Shipley ST; Lai SK
ACS Nano; 2024 Mar; 18(12):8733-8744. PubMed ID: 38469811
[TBL] [Abstract][Full Text] [Related]
10. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG.
McSweeney MD; Price LSL; Wessler T; Ciociola EC; Herity LB; Piscitelli JA; DeWalle AC; Harris TN; Chan AKP; Saw RS; Hu P; Jennette JC; Forest MG; Cao Y; Montgomery SA; Zamboni WC; Lai SK
J Control Release; 2019 Oct; 311-312():138-146. PubMed ID: 31454530
[TBL] [Abstract][Full Text] [Related]
11. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
[TBL] [Abstract][Full Text] [Related]
12. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
Bessen SY; Bessen MY; Yung CM
Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
[TBL] [Abstract][Full Text] [Related]
14. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review.
Keenan RT; Botson JK; Masri KR; Padnick-Silver L; LaMoreaux B; Albert JA; Pillinger MH
Semin Arthritis Rheum; 2021 Apr; 51(2):347-352. PubMed ID: 33601190
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
16. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
17. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
18. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
19. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
20. PEG-ing down (and preventing?) the cause of pegloticase failure.
Abeles AM
Arthritis Res Ther; 2014 May; 16(3):112. PubMed ID: 25142440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
